Tel: 318-675-7732, Fax: 318-675-8395
Cancer Cell Biology
Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas
Version of Record online: 30 SEP 2009
Copyright © 2009 UICC
International Journal of Cancer
Volume 126, Issue 10, pages 2282–2295, 15 May 2010
How to Cite
Beckner, M. E., Fellows-Mayle, W., Zhang, Z., Agostino, N. R., Kant, J. A., Day, B. W. and Pollack, I. F. (2010), Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int. J. Cancer, 126: 2282–2295. doi: 10.1002/ijc.24918
- Issue online: 22 MAR 2010
- Version of Record online: 30 SEP 2009
- Accepted manuscript online: 30 SEP 2009 12:00AM EST
- Manuscript Accepted: 2 SEP 2009
- Manuscript Received: 30 MAR 2009
- The Walter L. Copeland Fund for Cranial Research of The Pittsburgh Foundation. Grant Number: D2006-0379
- NIH. Grant Number: P01-NS40923
- The Nick Eric Wichman Foundation
- The Beez Foundation
- TATRC/Department of Defense
- USAMRAA Prime Award W81XWH-05-2-0066. Grant Number: R01-NS37704
- ATP citrate lyase;
- cell migration;
Glioblastomas, the most malignant type of glioma, are more glycolytic than normal brain tissue. Robust migration of glioblastoma cells has been previously demonstrated under glycolytic conditions and their pseudopodia contain increased glycolytic and decreased mitochondrial enzymes. Glycolysis is suppressed by metabolic acids, including citric acid which is excluded from mitochondria during hypoxia. We postulated that glioma cells maintain glycolysis by regulating metabolic acids, especially in their pseudopodia. The enzyme that breaks down cytosolic citric acid is ATP citrate lyase (ACLY). Our identification of increased ACLY in pseudopodia of U87 glioblastoma cells on 1D gels and immunoblots prompted investigation of ACLY gene expression in gliomas for survival data and correlation with expression of ENO1, that encodes enolase 1. Queries of the NIH's REMBRANDT brain tumor database based on Affymetrix data indicated that decreased survival correlated with increased gene expression of ACLY in gliomas. Queries of gliomas and glioblastomas found an association of upregulated ACLY and ENO1 expression by chi square for all probe sets (reporters) combined and correlation for numbers of probe sets indicating shared upregulation of these genes. Real-time quantitative PCR confirmed correlation between ACLY and ENO1 in 21 glioblastomas (p < 0.001). Inhibition of ACLY with hydroxycitrate suppressed (p < 0.05) in vitro glioblastoma cell migration, clonogenicity and brain invasion under glycolytic conditions and enhanced the suppressive effects of a Met inhibitor on cell migration. In summary, gene expression data, proteomics and functional assays support ACLY as a positive regulator of glycolysis in glioblastomas.
Glioblastoma (glioblastoma multiforme or Grade IV/IV astrocytoma) is a deadly, highly invasive type of brain tumor that responds poorly to conventional therapies. Glioblastoma cells thrive despite an irregular blood supply and a frequently hypoxic microenvironment. Compensatory mechanisms, including glucose uptake and glycolytic activity, are increased in these tumors.1–3 Our previous studies demonstrated that glioblastoma cells have sufficient glycolytic capacity to support tumor cell migration without mitochondrial participation.4, 5 On 2D gel analysis of protein lysates, enolase and other glycolytic enzymes were found to be increased within glioma pseudopodia, suggesting glycolytic support of the leading edge during cell migration.6
To identify key proteins involved with metabolic adaptations during migration, glioblastoma pseudopodia were analyzed on 1D gels which enables the evaluation of proteins beyond the size range of our previous 2D gel-based studies. Identification of increased ATP citrate lyase (ACLY), a 121 kDa enzyme in pseudopodia of glioblastoma cells, suggested consideration of increased ACLY as a potential adaptation in glioblastoma cells that disconnect from the vasculature during invasion. ACLY's cleavage of cytosolic citric acid,7 released from mitochondria or transferred across plasma membranes, suggests a role for ACLY in regulating glycolysis. Hypoxia and ischemia potentially induce accumulation of metabolic acids by production and lack of systemic removal. Also, uptake of cytosolic citric acid by tricarboxylic transporters on mitochondria is diminished during hypoxia.8 Therefore, diminished cleavage by ACLY allows cytosolic citric acid to inhibit phosphofructokinase 1 and other glycolytic enzymes,9–11 especially when cells are sensitized by hypoxic and ischemic stress. Although ACLY is better known for its role in production of lipids in normal conditions, its control of citric acid levels in the cytoplasm of glycolytic tumor cells may well provide a key adaptation during invasion when cells are more reliant on glycolysis.
Clinical and functional data regarding a metabolic role for ACLY in these tumors were obtained. Queries of the NIH's REMBRANDT database for brain tumors12 correlated ACLY gene expression with patient survival and co-expression of enolase 1 (ENO1) in their tumors. Real-time quantitative (RQ) PCR was performed on additional tumors to further examine gene expression.
The role of ACLY in cells under glycolytic conditions was investigated in cell migration and other functional studies using inhibitors of ACLY. Effects of inhibitors on migrated cells, quantified in Boyden chambers, included effects on their pseudopodia. The deformation and translocation of cells through filters in these assays requires energy so that migration with mitochondrial inhibition reflected the cells' reserve glycolytic capacity. Our earlier studies had shown that equal numbers of glioblastoma cells migrated under glycolytic and normal conditions.5 Dependence on real-time production of energy rather than energy stored as creatine phosphate characterizes high grade astrocytomas13 and simplifies the identification of effects on specific energy production pathways.
In this study, the differential effects in functional assays resulting from inhibition of ACLY in tumor cells, with and without exposure to glycolytic conditions, confirmed ACLY's role in protecting glycolysis. In our model, migration of glioblastoma cells was stimulated to enhance ATP production in normal and glycolytic conditions. Both serum and hepatocyte growth factor (HGF) or scatter factor, a known motogen,14 were used as chemoattractants when inhibitors of ACLY, hydroxycitrate and radicicol,15 were tested in assays. The results of functional assays coupled with gene expression and survival data suggest that ACLY is a promising target for inhibition of glioma invasion.
Material and Methods
Materials and cell culture
All materials were obtained from Sigma (St. Louis, MO) unless otherwise stated. Stock solutions of radicicol, 17-allylamino-17-demethoxygeldanamycin (17-AAG) and SU11274 (EMD Biosciences, Inc., La Jolla, CA), a Met kinase inhibitor, were prepared in dimethylsulfoxide. Potassium/calcium hydroxycitrate (600 mg/g SuperCitriMax, InterHealth Nutraceuticals, Inc., Benicia, CA) was solubilized in Minimal Essential Medium (MEM) (Cellgro Media Tech, Herndon, VA). Human U87 and LN229 glioblastoma cell lines (American Type Culture Collection, Manassas, VA) were maintained in MEM with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). Half volumes of media were changed 1 d prior to each assay to normalize the cells' metabolic state. Antibody to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was obtained from Abcam, Inc. (Cambridge, MA). Anti-phosphorylated(p) ACLY (serine 454), anti-HSP90, and anti-Met (25H2) were obtained from Cell Signaling Technology (Beverly, MA). Horseradish peroxidase-labeled anti-mouse and anti-rabbit secondary antibodies were obtained from Kirkegaard & Perry Laboratories (Gaithersburg, MD). Protein standards, Multimark and Magic Mark, were obtained from Invitrogen.
Retrieval of pseudopodia from cultured cells
The method for obtaining pseudopodia from cells has been described in detail.6 Briefly, suspensions of 2 × 106/ml cells in MEM with 0.1% bovine serum albumin (BSA) were loaded in the upper wells of 4-well Boyden chambers (Neuro Probe, Gaithersburg, MD) that were assembled with 0.01% porcine gelatin-coated, polycarbonate filters (Neuro Probe) containing pores, 1− or 3−μm diameter × 9–μm in length, to separate the upper and lower wells (Fig. 1a). The lower wells contained MEM with 0.1% BSA and chemoattractants, 2.5 ng/ml HGF and 0.1–1% FBS. Chambers were incubated at 37°C in 5% CO2 for 6 hr. Filters were removed, fixed in 100% methanol for 15 sec and placed on glass slides with migrated pseudopodia on their bottom surfaces. Unmigrated cells were very gently wiped completely from the top surface of the filter with large Kimwipes or cotton swabs using as little pressure as possible. Fresh Kimwipes were then pressed firmly on the filter for 30 sec to force adherence of pseudopodia to the glass (Fig. 1b). The filters were peeled from the slides leaving pseudopodia on the glass (Fig. 1c and 1d). If pseudopodia were not obtained with the first attempt, the filter was resubmerged in methanol for 5 sec and the process was repeated using a new glass slide. Yields were often scant and visualized best with the slide held against a dark background. Microscopy of Diff-Quik stained slides treated in a parallel fashion for harvesting pseudopodia confirmed the absence of nuclei in pseudopodial material for each cell line. Whereas filters with 3-μm pores worked well for U87 cells, cell lines with smaller size cells required filters with 1-μm pores. Pseudopodia on slides were stored at –80°C, batched and solubilized in lysate buffer consisting of 1.6 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, pH 8.0, containing 6 M urea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, 2 M thiourea and 20 mM dithiothreitol. Unmigrated cells, mostly whole cells, were allowed to adhere to filters in separate chambers and were transferred to glass slides as described above with transfer of the unmigrated cells to glass. Protein concentrations in the lysates were determined with the Bradford assay (Coomassie Plus Protein Reagent, Pierce, Rockford, IL).
Retrieval of pseudopodia from primary glioblastoma cells
Permission was obtained from the University of Pittsburgh's Institutional Review Board (IRB) for retrieval of pseudopodia from clinical specimens. Our method has been described.16 Briefly, after sufficient tissue for a diagnosis was obtained, the solid region of a glioblastoma was debulked with an ultrasonic suction aspirator (Integra Neurosciences, Plainsboro, NJ) that generated a tumor cell suspension in saline and blood. The specimen was examined on smears to verify purity of the tumor sample. Only anaplastic cells with glial fibrils typical of glioblastoma cells, erythrocytes, and occasional fragments of blood vessels were seen. The specimen was then centrifuged (5 min, 500 rpm) and the loosely pelleted tumor cells were loaded in Boyden chambers for retrieval of pseudopodia as described above.
One-dimensional gel electrophoresis of pseudopodia and unmigrated cells
Lysates of pseudopodia and unmigrated cells, equalized for total protein content (10 μg per lane) or with GAPDH, as indicated, were electrophoresed in separate lanes of 10% polyacrylamide gels under reducing conditions. It has been shown that protein and RNA expression of GAPDH remain stable in glial cell lines and tumors regardless of metabolic stress.17 Each gel was stained with Coomassie blue (Novex Colloidal Blue Stain Kit, Invitrogen) and destained with tap water. Protein standards were loaded as 8 μg per lane in each gel.
As previously described,18 gels were submitted to the Michigan Proteome Consortium, University of Michigan (Ann Arbor, MI). Robotic collection, destaining and trypsin treatment of plugs from the gels were performed on Coomassie blue-stained bands that were increased in lysates of U87 pseudopodia compared to unmigrated cells. Following trypsin digestion, peptides derived from the 120-kDa band were analyzed with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in 4700 and 4800 Proteomics Analyzers with TOF/TOF optics (Applied Biosystems, Foster City, CA). Optimized spectra calibrated by trypsin autolysis peptide ion signals were used to generate peak lists. Peptide mass fingerprint searches with the Mascot (http://www.matrixscience.com) program and the MS-Fit program (http://prospector.ucsf.edu) were used for protein identification utilizing NCBI and SwissProt databases. The search parameters have been described.18 Protein identifications were accepted when observed and predicted Mr's were consistent and scores indicated nonrandom identifications at the p < 0.05 level of significance. For immunoblotting of pseudopodia and unmigrated cells, gel contents were transferred onto polyvinylidene difluoride membranes (Invitrogen), blocked (Detector Block, Protein Detector Western Blot Kit Lumi-GLO System, Kirkegaard & Perry Laboratories, Gaithersburg, MD) and reacted with primary antibodies, anti-pACLY (1:250), anti-GAPDH (1:1000) and anti-HSP90 (1:333). Secondary antibodies, horseradish peroxidase-labeled anti-mouse and anti-rabbit (1:1000) were used for anti-pACLY, and anti-GAPDH and anti-HSP90, respectively. Immunoreactive bands were visualized via chemiluminescence and the blots were scanned.
Queries of the REMBRANDT database
Gene expression (Affymetrix) and Kaplan-Meier survival data for ACLY and the gene encoding enolase, ENO1, were queried online in 2008–2009, by following the site's instructions for “simple search.”7 Initially, queries were based on averages of the probe sets (termed reporters or locaters), the only data available prior to 2009. The database of 179 gliomas in May, 2008, had been expanded to 201 gliomas by February, 2009. Newer versions of REMBRANDT included results from separate probe sets, 4 and 5 for ACLY and ENO1, respectively. These results are available on pull-down menus under the button for “reporters” and were used in this study to investigate relationships between ACLY and ENO1 with chi square and correlation coefficient (r) analyses.
Real-time quantitative PCR
With the University of Pittsburgh IRB's approval, RNA expression was studied in frozen samples of glioblastomas resected from 24 patients (average age of 62.9 years, range of 19–81 year) provided by the University of Pittsburgh Brain Tumor Tissue Bank. Nucleic acid extraction, either an automated method via MagNA Lyser, MagNA Pure Compact, and MagNA Pure Compact Nuclei Acid Isolation Kit I (Roche Diagnostics Corp., Indianapolis, IN) or a manual method (pulverization of frozen tissue into lysate buffer, RNAeasy Plus Micro Kit (Qiagen, Valencia, CA) and homogenization with a syringe and needle) were followed by RNA purification with the RNAeasy Plus Micro Kit. For expression analysis, cDNAs were prepared from purified RNA of the tumor samples and pooled reference non-malignant brain tissue samples obtained from 23 adults, average age of 68.3 years, range of 23–86 years (First Choice Human Brain Reference RNA, Ambion Applied Biosystems, Austin, TX). Sufficient RNA for further analysis was obtained from 22 of the 24 frozen tumor samples. The cDNAs in tumor and reference samples were analyzed in triplicate wells for expression of ACLY, ENO1, ACTB (encodes actin B) and GAPDH and human genomic DNA and reverse transcription controls were tested in single wells of the same 96-well plates (Custom R2 PCR Arrays, SuperArray Biosciences, Corp., Frederick, MD). Primers for the genes and controls (preloaded on the custom plates) had been tested for specificity and equal efficiencies of amplification by the manufacturer and were confirmed by dilution curves in our laboratory (not shown). The cDNA samples were loaded with RT2 SYBR Green/ROX PCR Master Mix (SuperArray Biosciences Corp.). Amplification with data retrieval was performed on the ABI 7500 Prism Thermocycler System (Applied Biosystems, Foster City, CA). The delta-delta crossing threshold (ddCt) method was used to determine fold increases of each gene of interest in the tumor samples compared with the nonmalignant reference sample with the averaged values of 2 house keeping genes used for normalization. The dCt for each gene in an assay equaled Ct (gene of interest) − average Ct (house keeping gene). The ddCt for each gene equaled dCt (tumor sample) − dCt (reference nonmalignant brain sample). The fold-change for each gene from the normal reference sample to the tumor sample was calculated as 2-ddCt (the negative ddCt exponential function of 2).
Confluent cells were trypsinized and allowed to recover in MEM containing at least 10% FBS for 2 hr at 37°C. Incubation in MEM lacking phenol red optimized recovery. Cells, 1.5 × 106/ml, in MEM (with phenol red), with 0.1% BSA were loaded in the upper wells of modified Boyden chambers assembled with gelatin-coated filters (8-μm pores). The lower wells contained MEM (with phenol red), 0.1% BSA and chemoattractants, 2.5 ng/ml HGF and 1% FBS. The chambers were incubated at 37°C for 5–6 hr in 5% CO2. Glycolytic conditions were generated by suppression of cytochrome oxidase in mitochondrial respiration with 27 mM NaN3. Our earlier study demonstrated that 10–50 mM NaN3 did not inhibit cell migration under normoxic or hypoxic conditions.5 Multiple studies, including investigations of astrocytic cells, have used sodium azide to generate chemical hypoxia.19–29 The inhibitors, hydroxycitrate, radicicol, 17-AAG and SU11274, were added in the concentrations indicated. Control wells included the highest concentrations of vehicle used in the dose-response curves. Upon completion of the assays, the migration filters were stained with Diff Quik (Fisher Scientific, Pittsburgh, PA) and analyzed. The pellets of migrated cells were digitized using a transparency scanner (Epson Perfection 4990 PHOTO, Epson America, Long Beach, CA) and densitometry software (UN-SCAN-It gel, Silk Scientific, Orem, UT) with correction for background density of the filters. Results of migration assays (at least 3 assays with 4 replicates each) were stated as percent of control migration (no inhibitory drugs) under either normal or glycolytic (mitochondria inhibited) conditions. Analysis of cell viability at 6 hr, as indicated by trypan blue exclusion, was performed with light microscopy.
Suspended U87 cells, treated with NaN3 (27 mM), hydroxycitrate (3 mM), both NaN3 and hydroxycitrate, or no inhibitors for 5 hr in MEM (with phenol red) containing 1% FBS and 0.1% BSA, were centrifuged (5 min, 500 rpm), resuspended in MEM containing 10% FBS and plated, 250 cells per well, on 6-well plates. After 10 d in culture the cells were stained with Diff Quik and their colonies were manually counted in each well.
Cell invasion of rat brain slices
Brains of rats (Harlan Sprague-Dawley) were sliced in a rat brain sagittal matrix (Kent Scientific Corp., Torrington, CT). The slices were transferred to 6-well plates coated with Matrigel (BD Biosciences, Bedford, MA). Sterile transfer pipets with 0.5 cm diameter stems (Fisher Scientific) were cut into 1 cm segments with inclusion of a flared end for each so that funnels were formed. Stems of the funnels were used to punch out 1 × 5 mm discs of fresh brain tissue resting on Matrigel. The funnels containing wedged brain slices (1 mm thick) were placed with their flared ends upright on 8-chamber glass culture slides (BD Biosciences). Trypsinized U87 cells, recovered in phenol red-free MEM containing 20% FBS for 2 hr at 37°C, were labeled with a red fluorescent dye, the chloromethyl derivative of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine (CM-DiI Cell Tracker (Invitrogen). Cells were centrifuged, resuspended at 0.5 × 106/ml in Matrigel and then 50,000 cells (100 μl) were immobilized on the rat brain slices wedged in funnels as Matrigel solidified. A 2-well system with gradients was created by adding MEM (with phenol red) on top of the cells embedded in the layer of solidified Matrigel overlying the brain slice in the funnel, checking for leakage, and then adding media with chemoattractants (5 ng/ml HGF and 5% serum) outside the funnel sitting in a plate well. Hydroxycitrate was added to both sides of the brain slices as indicated. After 7 d at 37°C in 5% CO2, funnels with brain sections were fixed overnight in 10% formalin and the bottom edges of tissue were inked. Routine hematoxylin and eosin (H&E) sections were prepared. The bottom edges of brain slices were examined to detect tumor cells labeled with CM-DiI in comparison with host cells seen only in the H&E sections. Cell counts were obtained using a BHS-RFC reflected light fluorescence attachment (Olympus Corp., Center Valley, PA) with the appropriate filter for CM-DiI.
Chi-square analysis was performed with one degree of freedom in 2-x-2 tables. Correlation coefficients, trendlines and the levels of significance for regression in the REMBRANDT expression and RQ-PCR data were also obtained. Significance of correlation coefficients obtained from REMBRANDT data was determined by the p values of the student t statistics. Regression modeling was performed in S-Plus on RQ-PCR data (v. 7.0 for Windows, Insightful Corp., Seattle, WA) to derive best slope-parameter estimates between ENO1 and ACLY expression results. Outlier detection was based on detection of a difference greater than 3 SD from the average for the other residuals in the regression model. The means with 95% confidence intervals (CIs) and significant differences (p < 0.05) with 2-tailed student t tests were determined for tumor and nonmalignant reference brain tissue samples in expression studies and for tumor cells in functional assays, with and without exposure to inhibitors or glycolytic conditions. In the functional studies each data point was converted to the percent of the average control value (cells with no inhibitor) obtained in the same assay to correct for assay-to-assay variation. Concentrations of inhibitors (IC50's) that suppressed cell migration to 50% of levels exhibited by control cells (no inhibitors), were derived from equations for trendlines of the dose curves (Microsoft Office Excel 2003). Data points greater than 3 SD from the mean were treated as outliers.
Identification of ACLY in lysates of glioblastoma pseudopodia
Unmigrated U87 cells and their pseudopodia were harvested as lysates from filters containing 3- and 1-μm diameter pores. The lysates were equalized for total protein, electrophoresed, stained with Coomassie blue and visually compared. A 120-kDa band that was increased in the U87 pseudopodia (Fig. 2a) was excised and digested with trypsin. It was identified by mass spectrometry (MS) as ACLY isoform 2 (Homo sapiens, Accession No. 38569423, Mr = 120,608, protein score = 165 with CI% = 100 and total ion score = 130 with CI% = 100) with 2 peptides, R.GGPHYQEGLR.V (observed 1090.50, missed cleavage = 0, ion score = 39, CI% = 98.955, Mascot, S/N = 111, resolution = 7181) and K.WGDIEFPPPFGR.V (observed 1417.67, missed cleavage = 0, ion score = 53, CI% = 99.959, Mascot, S/N = 153, resolution = 12071). The MALDI-TOF/TOF-MS/MS spectrum for an ACLY peptide is shown (Fig. 2b). Identification of the lower molecular weight band (68 kDa) as BSA has been previously described in pseudopodia of glioblastoma cells.18 Lysates of pseudopodia and unmigrated glioblastoma cells were immunoblotted to compare levels of pACLY. Levels of HSP90 were also compared. Pseudopodia formed by U87 cells on filters with 3– and 1–μm diameter pores demonstrated 3.5-fold and 2.4-fold elevations of pACLY (125 kDa), respectively, compared with unmigrated cells. The loading control was GAPDH and loading equalized by total protein was also similar. In contrast, the levels of HSP90 (92 kDa) in U87 pseudopodia (3- and 1-μm) fell by 46% and 39%, respectively, compared with unmigrated cells. The levels of GAPDH (36 kDa) in pseudopodial lysates (3- and 1-μm diameters) were 91% and 95%, respectively, of the levels in unmigrated cell lysates (Fig. 2c). The immunoreactive band that reacted with anti-pACLY in pseudopodia formed by aspirated primary glioblastoma cells had a lower Mr than intact pACLY. However, its size (53 kDa), was the same as a predicted digestion product (DP) of ACLY that is known to retain activity.30, 31 The levels of pACLY-DP were 4.7-fold greater in primary tumor cell pseudopodia than in unmigrated cells. In contrast, the levels of HSP90 in the primary cell pseudopodia were much lower, only 7% of the unmigrated cells. Strong positive staining of the pseudopodial lysate on this immunoblot for glial fibrillary acidic protein has been previously shown.16 Loading was approximately equalized by GAPDH. Levels of GAPDH in lysates of primary cell pseudopodia (limited material available) were 84% of those in unmigrated cells (Fig. 2d). Only the 36 kDa band of GAPDH was used for equalizing loading of viable cellular material. Results with loading equalized by reactivity for anti-β-actin also demonstrated increased ACLY in the pseudopodia (not shown).
Queries of the national REMBRANDT database of brain tumors
Expression of ENO1, the gene encoding enolase, a variably expressed glycolytic enzyme, was used as an indicator of glycolytic activity. Affymetrix gene expression data with survival information was available from multiple institutions in the NIH's REMBRANDT database of brain tumors.12 The levels of gene expression for ACLY and ENO1 were increased at least 2-fold in 85 (42%) and 96 (48%), respectively, of 201 gliomas when results of all probe sets (reporters) available in the database were combined for each gene. The gliomas included a subset of 109 glioblastomas. The survival on Kaplan Meier plots of patients with gliomas showed a significant adverse association with increased expression of ENO1 as determined using 5 probe sets (reporters) with p values that ranged from 6.0 × 10−4 to 0.0057 (Table 1, Column 4). Survival was also adversely associated with increased ACLY expression as assessed using 4 probe sets with p values that ranged from 8.0 × 10−4 to 0.018 (Table 1, Column 9). By chi square analysis, the association between increased expression of ACLY and ENO1, as indicated by all of probe sets collectively, was highly significant, p = 3.85 × 10−5 and p = 0.00255, in 201 gliomas and 109 glioblastomas, respectively. Correlation analysis was performed to determine the relationship between increased gene expression for ACLY and ENO1 as indicated by the number of probe sets indicating increased expression in the same tumors with zero to a maximum of 4 and 5 probe sets for ACLY and ENO1, respectively. The correlation coefficient, r = 0.972, for the number of Affymetrix and Unified Gene probe sets indicating at least 2-fold increased gene expression for ACLY and ENO1 in each glioma was highly significant with a 2-tailed student t statistic of 9.248, p < 0.0005. In glioblastomas, r = 0.990, for the same relationship of ACLY and ENO1 probe set results in each tumor with a 2-tailed student t statistic of 15.692, p < 0.00005. The mean numbers of probe sets with 95% CI indicating increased expression of ACLY are graphed on the y axis against the numbers of probe sets indicating increased expression of ENO1 in each glioblastoma on the x axis is shown in Figure 3a.
Real-time quantitative PCR results
The relationship between ENO1 and ACLY was then tested with another technique on a different set of glioblastomas that were surgically resected at the University of Pittsburgh. The expressions of ENO1 and ACLY in 22 tumors obtained with RQ-PCR using the ddCt method were examined with correlation analysis. Studies of the first 6 glioblastomas tested showed that normalization with averaged values of both housekeeping genes, ACTB and GAPDH, yielded comparable r values to using either housekeeping gene alone (not shown). The graphical results of the 22 glioblastomas tested indicated that there was 1 outlier that was discarded after examination of a best-fit regression model. The outlier was greater than 3 SD from the average residual value of the other data points. The 21 residual values remaining were approximately normally distributed (not shown). The value of r between ACLY and ENO1 in 21 tumors was 0.756, a highly significant result with a 2-tailed student t statistic of 5.05, p < 0.0001 (Fig. 3b). The best-fit regression model also indicated statistical significance of the relationship between between ENO1 and ACLY, p < 0.001. The coefficients of variation for dCts of ACLY and ENO1 in the reference sample (6 assays) were 0.055 and 0.087, respectively. The average Cts with 95% CIs for the human genomic DNA contamination control and reverse transcription control were 32.87 ± 0.29 and 21.67 ± 0.46, respectively, for the tumor samples and 32.86 ± 0.67 and 20.69 ± 0.67 for the reference samples, respectively, with no significant differences between the sample types, p < 0.05.
Suppression of cell migration with inhibition of ACLY by hydroxycitrate
A potassium/calcium salt of hydroxycitrate, a competitive inhibitor of ACLY,32 at a concentration of 0.3 mM suppressed U87 cell migration dependent on glycolytic ATP (mitochondria inhibited) but not under normal conditions when mitochondrial ATP could be generated (Fig. 4a). As a negative control, 0.3–3 mM potassium citrate did not have a suppressive effect on U87 cell migration in glycolytic or normal conditions and its slight suppression at 12 mM under glycolytic conditions was not significant (not shown). Glycolytic and normal migration of LN229 cells was suppressed at 3 and 24 mM hydroxycitrate, respectively (Fig. 4b). Under glycolytic conditions the IC50's for hydroxycitrate were 16.7 and 12.1 mM for U87 and LN229 cells, respectively. Cell viability was unaffected during the assays.
Suppression of cell migration with inhibition of ACLY by radicicol
Radicicol, an inhibitor of ACLY and HSP90, was tested under glycolytic and normal conditions. HSP90 is a chaperone for Met and other kinases and suppression of its activity can have widespread effects on cell migration. Migration of U87 cells in glycolytic and normal conditions was significantly inhibited by 17 μM radicicol (Fig. 5a). Migration of LN229 cells in both types of conditions was also suppressed by radicicol (Fig. 5b). In addition, 17-AAG, another inhibitor of HSP9033 whose effects on ACLY are unknown, significantly inhibited U87 cell migration in both conditions at 17 μM (not shown). LN229 cells in glycolytic conditions were also sensitive to 17 μM 17-AAG (not shown). The IC50's of radicicol and 17-AAG for U87 cells were 38.5 and 61.3 μM, respectively, under glycolytic conditions, and 53.2 and 93.3 μM, respectively, in normal conditions. The IC50's of radicicol and 17-AAG for LN229 cells were 20.8 and 39.3 μM, respectively, in glycolytic conditions, and 23.4 and 80.8 μM, respectively, in normal conditions. Cell viability was unaffected during the assays. Prior to the 5–6 hr assays the glioblastoma cells were not preincubated with these drugs. The relatively high inhibitory amounts of 17-AAG required for the cell concentrations (2 million/ml) used in Boyden chambers with no pre-assay drug exposure were within the micromolar range required for high numbers of tumor cells in short chemotaxis assays.34
Hydroxycitrate-enhanced suppression of cell migration by SU11274
Stimulation of Met enhances glioblastoma cell migration. Accordingly, the Met kinase inhibitor SU11274,35–38 at 2.8 μM suppressed migration of U87 cells significantly (p < 0.05) in normal and glycolytic conditions. Significant suppression of glycolytic LN229 migration was achieved at comparable concentrations but normal (no mitochondrial inhibition) migration was resistant (not shown). When hydroxycitrate (3 mM) was combined with SU11274 (2.8–22.5 μM), a significant (p < 0.05) additive suppressive effect on glycolytic U87 cell migration resulted. In 4 assays under glycolytic conditions, the IC50 of SU11274 for U87 cells, 14.2 μM, was reduced to 7.47 μM when combined with 3 mM hydroxycitrate. The pellets of migrated cells are shown in Figure 6a with the results graphically represented in Figure 6b. SU11274's suppressive effect on LN229's glycolytic migration was not enhanced by 3 mM hydroxycitrate (not shown).
Suppression of clonogenic potential and brain slice invasion with inhibition of ACLY
Hydroxycitrate suppressed the clonogenic potential of glycolytic U87 cells. Test cells were exposed to 3 mM hydroxycitrate and glycolytic conditions (inhibition of mitochondria) for 5 hr prior to being plated for 10 d of culture in 2 assays. Significant differences (p < 0.05) were detected when hydroxycitrate-treated cells were compared with cells unexposed to hydroxycitrate or NaN3 (mitochondrial inhibitor) or to NaN3 alone (Fig. 7a). In another type of functional assay, hydroxycitrate suppressed U87 cell invasion through tissue slices of rat brain maintained for 7 d in glycolytic conditions (NaN3 present). The cells invaded brain slices in the presence of a chemoattractant gradient generated by 5 ng/ml HGF and 5% FBS. Significant suppression (p < 0.05) of invasion by 3 and 12 mM hydroxycitrate was 37% and 38%, respectively, compared with control (no hydroxycitrate) in 3 assays that are summarized in Figure 7b. Two of the 12 data points obtained for 3 mM hydroxycitrate were outliers and were not included.
After discovery of ACLY's increased distribution in glioblastoma pseudopodia, 2 glioblastoma cell lines were examined to determine the significance of ACLY's role in regulating tumor cells in glycolytic conditions. We previously identified glycolytic enzymes as the most prominent group of proteins increased in U87 pseudopodia on 2D gels, with enolase included among the increased glycolytic enzymes.6 ACLY is related to glycolysis via its breakdown of cytosolic citric acid. Brain tissue of suckling rats and cultured astrocytes are known to release citric acid from mitochondria.39–41 Also, an enhanced rate of citric acid release to the cytoplasm from mitochondria has been noted for poorly differentiated versus well-differentiated hepatomas.42 Although studies on the release of citric acid from mitochondria have not been performed in astrocytic tumors, citric acid levels in brain tumors are higher than in nonmalignant brain.43, 44
Others have reported that hypoxia, a glycolytic condition, stimulates glioblastoma cell migration45, 46 and it is well known that hypoxic tumor cells with increased glycolytic capacity resist many drugs.47–55 Glioblastomas commonly exhibit large areas of hypoxia in situ, with the potential for accumulation of intracellular metabolic acids, such as lactic and citric acid. Although increased levels of these acids should impair glycolysis, glioblastomas paradoxically upregulate the glycolytic pathway to levels that not only sustain viability but also promote profound invasiveness in an adverse environmental milieu. The rapid responsiveness of the glycolytic pathway56 as well as its simplicity offer advantages to glioblastoma cells in harsh microenvironments provided it can be protected from acidosis. The simplicity of the glycolytic pathway compared with mitochondria represents a smaller collective target in regard to the numbers of proteins and genes that are affected by drugs, toxins and genetic instability.
Therefore, enzymes and other proteins that protect glycolytic activity from acidosis need to be identified and investigated as targets to improve therapies of these invasive tumors. We previously investigated tumor cell metabolism of lactic acid, the inhibitory by-product of anaerobic glycolysis.5 Cytosolic citric acid also normally “brakes” glycolysis but its inhibitory effects appear to be negated when cleaved by ACLY, as illustrated in Figure 8. This study demonstrated enhanced levels of ACLY in pseudopodia, decreased patient survival associated with increased expression of ACLY in brain tumors, coexpression of increased ACLY and ENO1 and functional suppression of glioblastoma cells by a competitive inhibitor of ACLY, with specificity for glycolytic conditions. Thus, these results support ACLY as playing a protective role for the glycolytic pathway in glioblastomas. We hypothesize that ACLY's well established role in lipid synthesis under normoxic conditions is not responsible for the effects of ACLY's inhibitors that preferentially suppress glycolytic rather than normoxic cell migration.
Identification of proteins distributed to tumor cell pseudopodia should highlight those enzymes that play important roles in dynamic, energy-consuming cellular functions, such as migration. In that context, our detection of increased ACLY within pseudopodia of glioblastoma cells, including primary tumor cells, suggests that ACLY is important in promoting tumor invasion due to its protection of the glycolytic pathway in motile cellular extensions. Metabolism of citric acid via ACLY relieves inhibition of phosphofructokinase 1 and other glycolytic enzymes in tumor cells to putatively increase tolerance for ischemia. Suppression of ACLY inhibited cell migration under glycolytic conditions with no effect (or a much smaller one) on cell migration in normal conditions which supports a specific role for ACLY in protecting glycolysis.
Others have hypothesized that increased ACLY is necessary for the growth of tumor cells via production of acety-CoA for lipid synthesis so that inhibition of ACLY effectively blocks the growth of tumors.57 The production of acetyl-CoA via ACLY may also be involved in histone acetylation.58 Our 6 h migration studies were too short to be influenced by cell proliferation, and thus we do not address these roles for ACLY during normoxia. However, ACLY's production of acetyl-CoA in normoxia may constitute another physiologically relevant advantage of targeting ACLY in metabolic tumor treatments. The brain is rich in lipids that are available to invasive tumor cells in either normal conditions or hypoxia. The brain contains 25% of the body's cholesterol59 and exogenous lipids are supplied from the bloodstream to the brain.60 In hypoxia the supply of extracellular lipids to invasive tumor cells may be crucial since acetyl-CoA metabolism for lipid synthesis is diminished. When ATP levels fall compared with AMP in hypoxic normal cells, AMP-activated protein kinase suppresses lipid synthesis from acetyl-CoA by inhibition of acetyl-CoA carboxylase and lowering its affinity for citrate, an allosteric activator.61 However, exogenous lipids can be delivered to hypoxic tumor cells in vivo through the permeable blood brain barrier found in glioblastomas. Exogenous lipids (serum and BSA) were provided in these assays to support cell migration and to minimize synthesis of lipids as a variable. Pseudopodia have demonstrated a strong affinity for albumin in support of the hypothesis that exogenous lipids can be utilized by glioblastoma cells.18
A soluble form of hydroxycitrate, a competitive inhibitor of ACLY, was used to assess ACLY's functional role in glycolysis in vitro. Hydroxycitrate is derived from the fruit of Garcinia cambogia and other Garcinia species. Hydroxycitrate is poorly absorbed and is required in relatively large amounts to compete with endogenous citric acid. Studies have shown that humans can safely ingest 13.5 g of hydroxycitrate per day with plasma levels of 82 mg/l (0.39 mM) achieved,62, 63 and it has been shown to cross the blood brain barrier in rats to some extent.64 Although poor absorption and the high levels required for competition with citric acid limit the usefulness of hydroxycitrate, the functional results demonstrated here justify future development of noncompetitive inhibitors with specificity for ACLY. Combining citric acid with hydroxycitrate was not studied here in view of the potential for competition to occur at cell membrane tricarboxylate transporters but should also be considered.
Another inhibitor, radicicol, also suppressed cell migration with greater specificity for glycolytic conditions. This effect was attributed, at least in part, to radicicol's effect on ACLY, whereas its weaker effect on migration under normal conditions was attributed to its inhibition of HSP90. Decreased and increased levels of HSP90 and ACLY, respectively, in pseudopodia were consistent with attributing radicicol's effects on the leading edge of glycolytic migrating cells to its suppression of ACLY.
Clinical relevance for ACLY's role in brain tumor invasion was indicated by detection of increased ACLY in the pseudopodia formed by primary glioblastoma cells aspirated from a fresh tumor. Moreover, we detected significantly decreased survival among glioma patients who had increased expression of ACLY in the REMBRANDT database as well as a correlation between levels of ACLY and ENO1 that encodes a key glycolytic enzyme, enolase 1.
In summary, our data support ACLY as a newly identified positive regulator of glycolysis in glioblastomas that can be targeted to suppress hypoxic cell migration and invasion (Fig. 8). Thus, ACLY serves as not only a target in oxygenated cells for suppression of lipid synthesis and histone acetylation, as shown by others, but also as a susceptible target in hypoxic cells to restore inhibition of glycolysis, as shown in these studies. The enhanced pseudopodial distribution of ACLY, association of its increased gene expression with decreased survival in glioma patients, strong association of increased ACLY expression with that of ENO1 in gliomas and glioblastomas and ACLY's participation in tumor cell migration, clone formation and invasion are all findings that support ACLY as a positive regulator of glycolysis in glioblastoma cells. Overexpression of ACLY in nonsmall cell lung carcinoma and hepatocellular carcinoma compared with normal parenchyma has also been reported,65, 66 suggesting that ACLY may represent a common target among highly malignant tumors. Furthermore, targeting glycolytic adaptations in brain tumor cells, such as increased levels of ACLY, is a therapeutic metabolic strategy that can be combined with other treatments, in keeping with results obtained for a similar strategy in several other types of malignant tumors.67–70 These studies suggest that suppression of glycolysis via inhibition of ACLY is functionally effective and sensitizes glioblastoma cells to nonmetabolic inhibitors when mitochondrial function is impaired. This approach to inhibit hypoxic tumor cells would potentially complement antiangiogenesis therapies that compromise the blood supply to tumor cells.
We acknowledge the Repository of Molecular for Brain Neoplasia Database (REMBRANDT) created and maintained by the NINDS, NCI, at the NIH for the availability of information on ACLY and ENO1. We thank Dr. Douglas E. Moul, MD, MPH, Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA (relocated to Departments of Psychiatry and Neurology, Louisiana State University Health Sciences Center-Shreveport) for statistical advice. We thank The Michigan Proteome Consortium, University of Michigan, Ann Arbor, MI, and Dr. Melissa Melan, PhD and Mr. J.E. Dipaola, Department of Pathology, University of Pittsburgh, for technical assistance. We thank Dr. Ronald L. Hamilton, MD, and Ms. Colleen Lovell with the University of Pittsburgh Brain Bank with the cooperation of Dr. D.L. Lunsford, MD, for provision of primary brain tumor cells and tissue.
- 1High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer 1996; 74: 839–45., , , , , , , .
- 2Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res 1997; 17: 1903–11., , , , , .
- 3Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49: 6449–65., , .
- 4Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst 1990; 82: 1836–40., , , .
- 5Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest 2005; 85: 316–25., , , , , , .
- 6Proteomic characterization of harvested pseudopodia with differential gel electrophoresis and specific antibodies. Lab Invest 2005; 85: 316–27., , , , .
- 7The citrate cleavage enzyme. I. Distribution and purification. J Biol Chem 1959; 234: 2544–7..
- 8Transport of malate and citrate into rat brain mitochondria under hypoxia and anesthesia. Neurochem Res 1979; 4: 355–64..
- 9The application of quantitative histochemistry to the pharmacology of the nervous system. Biochem Pharmacol 1962; 9: 173–80., .
- 10Effect of (−)-hydroxycitrate on the activities of ATP citrate lyase and the enzymes of acetyl-CoA metabolism in rat brain. Acta Biochim Pol 1976; 23: 227–34., , , .
- 11Control of phosphofructokinase from rat skeletal muscle. J Biol Chem 1976; 251: 7322–8., .
- 12Repository of Molecular Brain Neoplasia Database (REMBRANDT) v1.5.2, generated and maintained by the NCI and NINDS at NIH. Available at: http://rembrandt.nci.nih.gov, February, 2009 data.
- 13In vitro study of astrocytic tumour metabolism by proton magnetic resonance spectroscopy. Gen Physiol Biophys 2005; 24: 327–35., , , , , , , , .
- 14Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 2003; 52: 1391–9; discussion 1399., , , , , .
- 15Radicicol binds and inhibits mammalian ATP citrate lyase. J Biol Chem 2000; 275: 39231–6., , , , , .
- 16Tumor cells from ultrasonic aspirations of glioblastomas migrate and form spheres with radial outgrowth. Cancer Lett 2007; 255: 135–44., , , , , , .
- 17GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC Mol Biol 2007; 8: 55. Doi:10.1186/1471–2199-8–55., , , , , , , .
- 18Albumin marks pseudopodia of astrocytoma cells responding to hepatocyte growth factor or serum. Lab Invest 2006; 86: 1103–14., , , , .
- 19Glycogen in astrocytes: possible function as lactate supply for neighboring cells. Brain Res 1993; 623: 208–14., , .
- 20Effects of glucose deprivation, chemical hypoxia, and simulated ischemia on Na+ homeostasis in rat spinal cord astrocytes. J Neurosci 1998; 18: 3554–62., , .
- 21Astrocyte glucose metabolism under normal and pathological conditions in vitro. Dev Neurosci 1996; 18: 515–21., .
- 22Cytochrome oxidase inhibition: a novel animal model of Alzheimer's disease. J Geriatr Psychiatry Neurol 1992; 5: 93–101., , , , .
- 23Synergy between chronic corticosterone and sodium azide treatments in producing a spatial learning deficit and inhibiting cytochrome oxidase activity. Proc Natl Acad Sci USA 1996; 93: 1330–4., , , .
- 24Chronic in vivo sodium azide infusion induces selective and stable inhibition of cytochrome c oxidase. J Neurochem 1996; 66: 2606–11., , , .
- 25Effects of in vivo sodium azide administration on the immunohistochemical localization of kynurenine aminotransferase in the rat brain. Neuroscience 1999; 94: 269–77., , .
- 26Effects of chronic sodium azide on brain and muscle cytochrome oxidase activity: a potential model to investigate environmental contributions to neurodegenerative diseases. J Toxicol Environ Health A 2001; 63: 67–77., , .
- 27Neuroprotective role of δ-opiod receptors against mitochondrial respiratory chain injury. Brain Res 2009; 1252: 183–191., , , , , .
- 28Sodium azide induced neuronal damage in vitro: evidence for non-apoptotic cell death. Neurochem Res 2009; 34: 909–16., , , , , , .
- 29Acetyl-L-carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology 2008; 55: 223–9., , , , , , , .
- 30Isolation of enzymically active fragments formed by limited proteolysis of ATP citrate lyase. Eur J Biochem 1982; 125: 645–50., , .
- 31Structure of ATP citrate lyase from rat liver. Physicochemical studies and proteolytic modification. J Biol Chem 1976; 251: 5242–50., , , .
- 32Effects of natural extract of (−)-hydroxycitric acid (HCA-SX) and a combination of HCA- SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obes Metab 2004; 6: 171–80., , , , , .
- 33Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Top Med Chem 2006; 6: 1163..
- 34The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005; 65: 4929–38., , , , , , , , , , .
- 35The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004; 23: 5387–93., , , , , , , , , , , , et al.
- 36Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479–88., , , , , , , , , , , , et al.
- 37HGF protects rat mesangial cells from high-glucose-mediated oxidative stress. Am J Nephrol 2006; 26: 519–30., , , , .
- 38c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007; 13: 2246–53., , , , , , , .
- 39Lipogenesis in the brain of suckling rats. Studies on the mechanism of mitochondrial-cytosolic carbon transfer. Biochm J 1980; 188: 163–8., .
- 40First direct demonstration of preferential release of citrate from astrocytes using [13C]NMR spectroscopy of cultured neurons and astrocytes. Neurosci Lett 1991; 128: 235–9., , , , , .
- 41Multiple compartments with different metabolic characteristics are involved in biosynthesis of intracellular and released glutamine and citrate in astrocytes. Glia 2001; 35: 246–52., , , .
- 42Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria. The truncated. Krebs cycle and other metabolic ramifications of mitochondrial membrane cholesterol. J Biol Chem 1984; 259: 9997–10003., .
- 43Diversity of metabolic patterns in human brain tumors: enzymes of energy metabolism and related metabolites and cofactors. J Neurochem 1983; 41: 994–1010., , , , , , .
- 44Citrate in pediatric CNS tumors? AJ NR Am J Neuroradiol 2008; 29: 1006–1011., , , , .
- 45Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64: 920–927., , , , , , , , .
- 46Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004; 84: 397–405., .
- 47Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 1991; 64: 809–14., , , , , .
- 48Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin. Cancer Chemother Pharmacol 1987; 19: 282–6., , , .
- 49Role of hypoxia in anticancer drug-induced cytotoxicity for Ehrlich ascites cells. Cancer Res 1987; 47: 2407–12., .
- 50Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia. J Natl Cancer Inst 1989; 81: 1235–40., , .
- 51Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst 1990; 82: 684–92., , , .
- 52Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 2006; 58: 776–84., , , , , , .
- 53Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 1994; 58: 258–62., .
- 54Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells. Mol Cancer 2004; 3: 19., , , , , .
- 55STI571's inhibition of spontaneous cell motility in Boyden chambers shows specificity for cell type and non-hypoxic conditions. Proc Am Assoc Cancer Res 2002; 43: 1084., , .
- 56Cooperation and competition in the evolution of ATP-producing pathways. Science 2001; 292: 504–7., , .
- 57ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8: 311–21., , , , , , , , .
- 58ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009; 324: 1076–80., , , , , .
- 59Analysis of neurosterols and neurosteroids by mass spectrometry. Biochimie 2007; 89: 182–91., , .
- 60Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain. J Mol Neurosci 2001; 16: 159–65..
- 61Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 2005; 65: 2441–8., , , , , , , , , , , , et al.
- 62Bioefficacy of a novel calcium-potassium salt of (−)-hydroxycitric acid. Mutat Res 2005; 579: 149–62., , , , , .
- 63Effects of acute (−)-hydroxycitrate supplementation on substrate metabolism at rest and during exercise in humans. Am J Clin Nutr 2000; 72: 1445–50., , , , , .
- 64Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). Mol Cell Biochem 2002; 238: 89–103., , , , , .
- 65ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008; 68: 8547–54., , , , , , , , , , , , .
- 66Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 2005; 41: 1316–22., , , , , , , , , , , , et al.
- 672-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 2007; 67: 3364–70., , , , .
- 68Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression. Biochem Pharmacol 1995; 50: 1943–48., , , .
- 69ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. Cancer Res 2000; 60: 6776–83., , .
- 702-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004; 64: 31–4., , , , , , , .